

HETEROCYCLES, Vol. 75, No. 12, 2008, pp. 2937 - 2948. © The Japan Institute of Heterocyclic Chemistry
Received, 7th May, 2008, Accepted, 4th July, 2008, Published online, 10th July, 2008. COM-08-11426

**SYNTHESIS AND ANTIMICROBIAL EVALUATION OF SOME
BIS(THIOXOPYRIDINE), BIS(PYRAZOLO[3,4-*b*]PYRIDINE),
BIS(THIENO[2,3-*b*]PYRIDINE), BIS(1,3,4-THIADIAZOLE) AND
BIS-THIOPHENE DERIVATIVES**

Nabila A. Kheder,¹ Yahia N. Mabkhot,² and Ahmad M. Farag^{1,*}

¹Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt ²Department of Chemistry, Faculty of Science, King Saud University, 2455, Riyadh 11751, Saudi Arabia

* Corresponding author: E-mail: afarag49@yahoo.com

Abstract – Condensation of the *N,N'*-(ethane-1,2-diyl)bis(cyanoacetamide) (**1**) with aromatic aldehydes gave the corresponding *N,N'*-(ethane-1,2-diyl)-bis(2-cyano-3-phenylacrylamide) derivatives **2a-c**. The latter products react with 2-cyanothioacetamide to afford 1,2-bis(4-aryl-3,5-dicyano-6-mercapto-2-oxo-1,2-dihydropyridin-1-yl)ethane derivatives **5a-c**. Treatment of 1,2-bis(3,5-dicyano-6-mercapto-2-oxo-4-phenyl-1,2-dihydropyridin-1-yl)ethane (**5a**) or its *S*-methyl derivative **6** with hydrazine hydrate afforded 1,2-bis(3-amino-5-cyano-6,7-dihydro-7-methyl-6-oxo-4-phenyl-1*H*-pyrazolo[3,4-*b*]pyridin-1-yl)ethane (**7**). Reaction of bis(6-mercaptopyridine) **5b** with chloroacetone gave the 1,2-bis[2-acetyl-3-amino-6,7-dihydro-5-cyano-4-(4-methoxyphenyl)-6-oxothieno[2,3-*b*]pyridine-7-yl]ethane (**9**). Treatment of the bis(cyanoacetamide) **1** with phenyl isothiocyanate afforded *N,N'*-(ethane-1,2-diyl)bis[2-cyano-3-mercapto-3-(phenyl amino)acrylamide] (**11**) which reacts with hydrazonoyl halides **12a,b** or haloketones **15a-c** to give the corresponding *N,N'*-(ethane-1,2-diyl)bis[2-cyano-2-(3,5-disubstituted-2(3*H*)-1,3,4-thiadiazolylidene)acetamides] **14a,b** or *N,N'*-(ethane-1,2-diyl)bis[4-amino-5-substituted-2-(phenylamino)thiophene-3-carboxamide] **16a-c** derivatives, respectively. Antimicrobial evaluation of selected example of the newly synthesized compounds was carried out.

INTRODUCTION


Several substituted pyridine-2-thiones have been found to be useful as antibiotic,^{1,2} antiarteriosclerotic,³ antibacterial,⁴ antihyperglycemic⁵ and antifungal⁶ agents and as inhibitors of the blood coagulation

factor.⁷ Also, some thieno[2,3-*b*]pyridine derivatives are known to possess antiviral,⁸ antihypertensive⁹ and immunostimulating¹⁰ activities. They are also used as gonadotropin-releasing hormone antagonists¹¹⁻¹⁶ and as lipoxygenases inhibitors.¹⁷ Recently, bis(heterocycles) have received great deal of attention, not only for being model compounds for main chain polymers,¹⁸⁻²³ but also because many biologically active natural and synthetic products have molecular symmetry.²⁴

Encouraged by these findings and in continuation of our previous work aimed at the synthesis of a variety of heterocyclic systems for biological and pharmacological evaluation,²⁵⁻³³ we have found that *N,N'*-(ethane-1,2-diyl)bis(cyanoacetamide) (**1**), is a versatile, readily accessible building block for the synthesis of several new bisheterocyclic compounds of biological potency.

RESULTS AND DISCUSSION


N,N'-(Ethane-1,2-diyl)bis(cyanoacetamide) (**1**)³⁴ reacts with aromatic aldehydes to afford the corresponding *N,N'*-(ethane-1,2-diyl)bis(2-cyano-3-phenylacrylamide) derivatives **2a-c**^{35,36} (Scheme 1). The IR spectrum of compound **2c**, taken as a typical example of the series prepared, revealed absorption bands at 1674, 2214 and 3371 cm⁻¹ corresponding to carbonyl, nitrile and NH functions, respectively. Its ¹H NMR spectrum showed signals at δ 3.39, 8.18 and 8.60 D₂O-exchangeable due to CH₂, CH and NH protons in addition to two aromatic protons at δ 7.65 and 7.97.



Scheme 1


Treatment of the products **2a-c** with 2-cyanothioacetamide³⁷ furnished 1,2-bis(4-aryl-3,5-dicyano-6-mercapto-2-oxo-1,2-dihydropyridin-1-yl)ethane derivatives **5a-c** (Scheme 2). The IR spectrum of compound **5a**, taken as a typical example of the prepared series, revealed absorption bands at 1543, 1643, and 2217 cm⁻¹ corresponding to thiocarbonyl, carbonyl and nitrile functions, respectively. Its ¹H NMR spectrum showed signals at δ 3.4 and 13.1 D₂O-exchangeable due to CH₂ and SH protons in addition to an aromatic multiplet in the region δ 7.49-7.60. Compounds **5a-c** are assumed to be formed *via* an initial *Michael type* adducts **4** followed by an intramolecular cyclization³⁸ and dehydrogenation to the final products **5a-c** (Scheme 2). Alkylation of compound **5a** with methyl iodide afforded the *S*-alkyl derivative **6** (Scheme 3). The IR spectrum of **6** revealed absorption bands at 1620 and 2214 cm⁻¹ corresponding to

carbonyl and two nitrile groups, respectively. Its ^1H NMR spectrum revealed signal at δ 2.6 due to SCH_3 , signal at δ 3.4 due to CH_2 protons and an aromatic multiplet in the region 7.57-8.02.




Scheme 2

Reaction of the latter product with hydrazine hydrate gave 7,7'-(ethane-1,2-diyl)bis(3-amino-6,7-dihydro-6-oxo-4-phenyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carbonitrile) (**7**) (Scheme 3). The latter product was alternatively prepared from the reaction of the bispyridinethione derivative **5a** also with hydrazine hydrate to give **7** (Scheme 3). The ^1H NMR spectrum of compound **7** revealed signal at δ 4.3 due to CH_2 , in addition to two D_2O -exchangeable signals at δ 6.83 and 11.94 due to NH_2 and NH protons, respectively in addition to an aromatic multiplet in the region 7.51-7.62.




Scheme 3

Compound **5b** reacts with chloroacetone to give bis(thienopyridine) derivative **9** (Scheme 4). The IR spectrum of compound **8** revealed absorption bands at 1636, 1728, 2206, 3333 and 3425 cm^{-1} corresponding to two carbonyl, nitrile and amino functions, respectively. Its ^1H NMR spectrum showed signals at δ 2.35, 3.86, 4.22 and 7.95 D_2O -exchangeable due to CH_3CO , CH_3O , CH_2 and NH_2 protons in addition to an aromatic multiplet in the region δ 7.50-7.54.



Scheme 4


Treatment of the *N,N'*-(ethane-1,2-diyl)bis(cyanoacetamide) (**1**) with phenyl isothiocyanate, in dimethylformamide, and in the presence of potassium hydroxide, at rt, followed by treatment with dilute hydrochloric acid, afforded a yellow-colored product identified as *N,N'*-(ethane-1,2-diyl)bis[2-cyano-3-mercapto-3-(phenylamino)acrylamide] (**11**) (Scheme 5). The IR spectrum of the latter product showed absorption bands at 3375, 3286 and 2185 cm^{-1} due to two NH groups and a nitrile functions, respectively. Its ^1H NMR spectrum showed signals at δ 3.32 and three D_2O -exchangeable signals at δ 10.81, 10.97 and 11.94 due to CH_2 , 2 NH and SH protons, respectively, in addition to an aromatic multiplet in the region δ 7.08-7.79.



Scheme 5


Compound **11** reacts with the hydrazonoyl halide **12a,b**^{39,40} to afford the thiadiazole derivatives **14a,b** (Scheme 6). The IR spectrum of compound **14a**, taken as a typical example revealed absorption bands at

1666, 1713, 2218 and 3240 cm^{-1} corresponding to two carbonyls, nitrile and NH functions, respectively. Its ^1H NMR spectrum showed a triplet signal at δ 1.17 ($J = 7.2$ Hz) due to CH_3 and a quartet signal at δ 4.19 ($J = 7.2$ Hz) due to CH_2 of ethoxy protons, at δ 3.31 due to CH_2 and at δ 11.79 D_2O -exchangeable corresponding to NH in addition to aromatic protons in the region δ 7.22-7.84. The latter compounds were assumed to be formed *via* elimination of aniline molecule from the non-isolable intermediate to the final products **14a,b** (Scheme 6).



Scheme 6

Compound **11** reacts with 2-(bromoacetyl)benzothiazole (**15a**)⁴¹ to afford the corresponding thiophene derivative **16a** (Scheme 7). The IR spectrum of the isolated product showed absorption bands at 3400, 3352 and 1656 cm^{-1} characteristic for NH_2 and carbonyl groups, respectively. Its ^1H NMR spectrum showed signals at δ 3.47, 8.37 and 10.06 corresponding to CH_2 and two D_2O -exchangeable signals corresponding to two NH protons, in addition to an aromatic multiplet and NH_2 protons in the region δ 7.20-8.2. The foregoing spectral data supported the proposed structure **16a** and ruled out the other possible thiazole structure **17** (Scheme 6). Similarly, compound **11** reacted with 3-(bromoacetyl)benzo[*b*]pyran (**15b**)^{42,43} and 1-phenyl-2-bromoethanone (**15c**)⁴⁴ under similar reaction conditions and afforded the thiophene derivatives **16b,c**, respectively as shown in Scheme 7.



Scheme 7

EXPERIMENTAL

All melting points were measured on a Gallenkamp melting point apparatus. The infrared spectra were recorded in potassium bromide disks on a Pye Unicam SP 3300 and Shimadzu FT IR 8101 PC infrared spectrophotometers. The NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer. ^1H spectra were run at 300 MHz and ^{13}C spectra were run at 75.46 MHz in dimethylsulphoxide ($\text{DMSO}-d_6$). Chemical shifts were related to that of the solvent. Mass spectra were recorded on a Shimadzu GCMS-QP 1000 EX mass spectrometer at 70 e.V. Elemental analyses were carried out at the Microanalytical Center of Cairo University, Giza, Egypt. The biological evaluation of the products **5b**, **5c**, **14b** and **16b** were carried out in the Medical Mycology Laboratory of the Regional Center for Mycology and Biotechnology of Al-Azhar University, Cairo, Egypt.

N,N'-(Ethane-1,2-diyl)bis(cyanoacetamide) (**1**),³⁴ 2-cyanothioacetamide,³⁷ hydrazonoyl halides **11a**,³⁹ **11b**,⁴⁰ 1-(benzothiazol-2-yl)-2-bromoethanone (**15a**),⁴¹ 3-(2-bromoacetyl)-2*H*-chromen-2-one (**15b**),^{42,43} 2-bromo-1-phenylethanone (**15c**)⁴⁴ were prepared following the literature procedure.

N,N'-(Ethane-1,2-diyl)bis(2-cyano-3-arylacrylamide) derivatives 2a-c.

General procedure:

To an ethanolic solution of the bis(cyanoacetamide) **1** (0.194 g, 1 mmol) and the appropriate aromatic aldehyde (2 mmol), was added few drops of piperidine and the reaction mixture was refluxed for 4 h. The solvent was evaporated under reduced pressure and the residue was triturated with EtOH, filtered off, washed with EtOH and finally purified by recrystallization from DMF/EtOH to afford *N,N'*-(ethane-1,2-diyl)bis(2-cyano-3-arylacrylamide) derivatives **2a-c**.

N,N'-(Ethane-1,2-diyl)bis(2-cyano-3-phenylacrylamide) (**2a**).

Pale yellow crystals, yield: 0.22 g (60%), mp 210-211 °C; IR (KBr): 3310 (NH), 2208 ($\text{C}\equiv\text{N}$), 1668 ($\text{C}=\text{O}$) cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 3.40 (s, 4H, 2NCH₂), 7.56-7.99 (m, 10H, ArH's), 8.20 (s, 2H, 2CH), 8.64 (s, 2H, D₂O-exchangeable 2NH). Anal. Calcd for C₂₂H₁₈O₂N₄ (370.14): C, 71.34; H, 4.90; N, 15.13. Found: C, 71.36; H, 4.94; N, 15.10%.

N,N'-(Ethane-1,2-diyl)bis[2-cyano-3-(4-methoxyphenyl)acrylamide] (**2b**).

Pale yellow crystals, yield: 0.29 g (68%), mp 245-246 °C; IR (KBr): 3356 (NH), 2206 ($\text{C}\equiv\text{N}$), 1666 ($\text{C}=\text{O}$) cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 3.39 (s, 4H, 2NCH₂), 3.86 (s, 6H, OCH₃), 7.10 (d, 4H, ArH's, $J = 8.7$ Hz), 7.95-8.0 (d, 4H, ArH's, $J = 8.7$ Hz), 8.12 (s, 2H, 2CH), 8.47 (s, 2H, D₂O-exchangeable 2NH); ^{13}C NMR [$\text{DMSO}-d_6$] δ 38.75, 55.56, 102.76, 114.78, 116.86, 124.41, 132.34, 149.98, 161.65, 162.54. Anal. Calcd for C₂₄H₂₂O₄N₄ (430.16): C, 66.97; H, 5.15; N, 13.02. Found: C, 66.94; H, 5.17; N, 13.05%.

N,N'-(Ethane-1,2-diyl)bis[2-cyano-3-(4-chlorophenyl)acrylamide] (**2c**).

Pale yellow crystals, yield: 0.33 g (77%), mp 274-275 °C; IR (KBr): 3371 (NH), 2214 ($\text{C}\equiv\text{N}$), 1674 ($\text{C}=\text{O}$) cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 3.39 (s, 4H, 2NCH₂), 7.66 (d, 4H, ArH's, $J = 8.4$ Hz), 7.96 (d, 4H,

ArH's, $J = 8.4$ Hz), 8.18 (s, 2H, 2CH), 8.60 (s, 2H, D₂O-exchangeable 2NH). Anal. Calcd for C₂₂H₁₆O₂N₄Cl₂ (438.07): C, 60.15; H, 3.67; N, 12.75; Cl, 16.14. Found: C, 60.17; H, 3.69; N, 12.78; Cl, 16.12%.

1,2-Bis(4-aryl-3,5-dicyano-6-mercapto-2-oxo-1,2-dihydropyridin-1-yl)ethane derivatives 5a-c.

General procedure:

To a solution of the appropriate *N,N'*-(ethane-1,2-diyl)bis(2-cyano-3-arylacrylamide) derivatives **2a-c** (1 mmol) in EtOH (20 mL) was added 2-cyanothioacetamide (0.2 g, 2 mmol) and few drops of piperidine then the reaction mixture was heated under reflux for 2 h. The solid product was collected by filtration, washed with EtOH and then recrystallized from DMF/EtOH to give **5a-c**.

1,2-Bis(3,5-dicyano-6-mercapto-2-oxo-4-phenyl-1,2-dihydropyridin-1-yl)ethane (5a).

Yellow crystals, yield: 0.32 g (60%), mp 250-251 °C; IR (KBr): 1543 (C=S), 1643 (C=O), 2214 (C≡N), 2217 (C≡N) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.40 (s, 4H, 2NCH₂), 7.49-7.60 (m, 10H, ArH's), 13.10 (s, 2H, D₂O-exchangeable 2SH). Anal. Calcd for C₂₈H₁₆O₂N₆S₂ (532.08): C, 63.14; H, 3.03; N, 15.78; S, 12.04. Found: C, 63.12; H, 3.07; N, 15.80; S, 12.03%.

1,2-Bis[3,5-dicyano-4-(4-methoxyphenyl)-6-mercapto-2-oxo-1,2-dihydropyridin-1-yl]ethane (5b).

Yellow crystals, yield: 0.41 g (69%), mp 264-265 °C; IR (KBr): 1546 (C=S), 1638 (C=O), 2214 (C≡N) cm⁻¹. Anal. Calcd for C₃₀H₂₀O₄N₆S₂ (592.65): C, 60.80; H, 3.40; N, 14.18; S, 10.82. Found: C, 60.78; H, 3.45; N, 14.15; S, 10.87%.

1,2-Bis[4-(4-chlorophenyl)-3,5-dicyano-6-mercapto-2-oxo-1,2-dihydropyridin-1-yl]ethane (5c).

Yellow crystals, yield: 0.48 g (80%); mp > 300 °C; IR (KBr): 1547 (C=S), 1643 (C=O), 2217 (C≡N) cm⁻¹; ¹H- NMR (DMSO-*d*₆): δ 3.40 (s, 4H, 2NCH₂), 7.57-7.67 (m, 8H, ArH's), 13.05 (s, 2H, D₂O-exchangeable, 2SH). Anal. Calcd for C₂₈H₁₄O₂N₆S₂Cl₂ (601.49): C, 55.91; H, 2.35; N, 13.90; S, 10.66; Cl, 11.79. Found: C, 55.93; H, 2.33; N, 13.88; S, 10.68; Cl, 11.75%.

1,2-Bis(3,5-dicyano-6-methylthio-2-oxo-4-phenyl-1,2-dihydropyridin-1-yl)ethane (6).

The bis[6-mercapto-1,2-dihydropyridine] **5a** (0.53 g, 1 mmol) was dissolved in an ethanolic solution of sodium ethoxide [prepared from sodium metal (0.046 g, 2 mg atom) in EtOH (30 mL)], then methyl iodide (0.6 g, 4 mmol) was added gradually to the resulting solution. The reaction mixture was heated under reflux for 2 h, concentrated, allowed to cool, diluted with water. The precipitate that obtained was filtered off, washed with water and recrystallized from EtOH/DMF to produce **6** in 65% yield; mp 268-269 °C; IR (KBr): 1620 (C=O), 2214 (C≡N) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.60 (s, 6H, 2SCH₃), 3.40 (s, 4H, 2NCH₂), 7.54-8.02 (m, 10H, ArH's). Anal. Calcd for C₃₀H₂₀O₂N₆S₂ (560.65): C, 64.27; H, 3.60; N, 14.99; S, 11.44, found: C, 64.30; H, 3.62; N, 15.00; S, 11.47%.

7,7'-(Ethane-1,2-diyl)bis(3-amino-6,7-dihydro-6-oxo-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonit-rile) (7)

General procedure:

To a solution of bis(6-mercaptopyridine) **5a** (0.53 g, 1 mmol) or bis(6-methylthiopyridine) **6** (0.56 g, 1 mmol) in EtOH (20 mL), hydrazine hydrate (80%, 0.2 ml, 2 mmol) was added and the reaction mixture was refluxed for 4 h, and then left to cool. The solid product so formed was filtered off, washed with EtOH and dried. Recrystallization from EtOH/DMF afforded **7** in 55% and 48% yields from **5a** and **6**, respectively, mp 300-302 °C; IR (KBr): 3412, 3235, 3105 (NH, NH₂), 1666 (C=O), 2214 (C≡N) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 4.30 (s, 4H, 2NCH₂), 6.83 (s, 4H, D₂O-exchangeable, 2NH₂), 7.51-7.62 (m, 10H, ArH's), 11.94 (s, 2H, D₂O-exchangeable, 2NH). Anal. Calcd for C₂₈H₂₀O₂N₁₀ (528.18): C, 63.63; H, 3.81; N, 26.50. Found: C, 63.61; H, 3.85; N, 26.47%.

1,2-Bis[2-acetyl-3-amino-5-cyano-6,7-dihydro-4-(4-methoxyphenyl)-6-oxothieno[2,3-b]pyridin-7-yl]ethane (9).

The bis(6-mercaptopyridine) **5b** (0.59 g, 1 mmol) was dissolved in an ethanolic solution of sodium ethoxide [prepared from sodium metal (0.046 g, 2 mg atom) in EtOH (30 mL)], then chloroacetone (4 mmol) was added gradually to the resulting solution. The reaction mixture was heated under reflux for 2 h, concentrated, allowed to cool, diluted with water and left overnight. The precipitate that obtained was filtered off, washed with water and recrystallized from EtOH/DMF to produce pale yellow crystals.

Yield: 0.42 g (60%); mp 226-227 °C ; IR (KBr): 3425 and 3333 (NH₂), 2206 (C≡N). 1728 (C=O), 1636 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.35 (s, 6H, 2CH₃), 3.86 (s, 6H, 2CH₃), 4.22 (s, 4H, 2NCH₂), 7.14-7.52 (m, 8H, ArH's), 7.95 (s, 4H, D₂O-exchangeable 2NH₂). MS *m/z* (%) 704 (M⁺, 91.67). Anal. Calcd for C₃₆H₂₈O₆N₆S₂ (704.77): C, 61.35; H, 4.00; N, 11.92; S, 9.10. Found: C, 61.30; H, 4.03; N, 11.90; S, 9.08%.

***N,N'*-(Ethane-1,2-diyl)bis[2-cyano-3-mercapto-3-(phenylamino)acrylamide] (11).**

To a stirred solution of potassium hydroxide (0.11 g, 2 mmol) in DMF (20 mL) was added the bis(cyanoacetamide) **1** (0.194 g, 1 mmol). After stirring for 30 min, phenyl isothiocyanate (0.27 g, 2 mmol) was added to the resulting mixture. Stirring was continued for 6 h, and then the reaction mixture was poured over a cold solution of 0.5 N hydrochloric acid. The solid product that formed was filtered off, washed with water, dried, and finally recrystallized from EtOH /DMF mixture to afford yellow crystals of **11** in 60% yield, mp 224-225 °C; IR (KBr): 3375 (NH), 3286 (NH), 2185(C≡N), 1616 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.32 (s, 4H, 2NCH₂), 7.08-7.79 (m, 10H, ArH's), 10.81(s, 2H, D₂O-exchangeable, 2NH), 10.97 (s, 2H, D₂O-exchangeable, 2NH), 11.94 (s, 2H, D₂O-exchangeable, 2SH); MS *m/z* (%): 465 (M⁺+1, 93), 232 (M⁺/2, 89). Anal. Calcd for C₂₂H₂₀N₆O₂S₂ (464.56): C, 56.88; H, 4.34; N, 18.09; S, 13.80%. Found: C, 56.85; H, 4.30; N, 18.10; S, 13.82%.

Reaction of compound 11 with hydrazonoyl halides 12a,b or haloketones 15a-c**General Procedure.**

To a solution of the compound **11** (0.464 g, 1 mmol) in EtOH (20 mL), the appropriate hydrazonoyl halides **12a,b** or haloketones **15a-c** (2 mmol) were added. Triethylamine (0.2 mmol) was added dropwise and the reaction mixture was refluxed for 1 h then allowed to cool. The formed solid was filtered off, washed with EtOH, and recrystallized from DMF/EtOH to afford the corresponding bis-thiadiazoles **14a,b** or bis-thiophene derivatives **16a-c**.

***N,N'*-(Ethane-1,2-diyl)bis[2-cyano-2-[5-ethoxycarbonyl-3-(4-nitrophenyl)-2(3H)-1,3,4-thiadiazolylidene)acetamide] (14a).**

Green crystals, yield: 0.54 g (72%); mp 158-159 °C; IR (KBr): 3240 (NH), 2218 (C≡N), 1713 (C=O), 1666 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 1.17 (t, 6H, 2CH₃, *J* = 7.2 Hz), 3.31 (s, 4H, 2NCH₂), 4.19 (q, 4H, 2CH₂, *J* = 7.2 Hz), 7.22-7.84 (m, 8H, ArH's), 11.79 (s, 2H, D₂O-exchangeable 2NH). Anal. Calcd for C₃₀H₂₄O₁₀N₁₀S₂ (748.70): C, 48.13; H, 3.23; N, 18.71; S, 8.57. Found: C, 48.10; H, 3.22; N, 18.74; S, 8.55%.

***N,N'*-(Ethane-1,2-diyl)bis[2-cyano-2-[3-(4-nitrophenyl)-5-(thien-2-yl-carbonyl)-2(3H)-1,3,4-thiadiazolylidene)acetamide] (14b).**

Green crystals, yield: 0.64 g (77%), mp 240-241 °C; IR (KBr): 3109 (NH), 2195 (C≡N), 1668 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.32 (s, 4H, 2NCH₂), δ 7.23-8.28 (m, 14H, ArH's), 11.56 (s, 2H, D₂O-exchangeable 2NH). Anal. Calcd for C₃₄H₂₀O₈N₁₀S₄ (824.84): C, 49.51; H, 2.44; N, 16.98; S, 15.55. Found: C, 49.53; H, 2.42; N, 16.95; S, 15.57%.

***N,N'*-(Ethane-1,2-diyl)bis[4-amino-5-(benzothiazol-2-carbonyl)-2-(phenylamino)]thiophene-3-carboxamide (16a).**

Yellow crystals, yield: 0.53 g (65%); mp > 300 °C; IR (KBr): 3420-3333(NH₂+2NH), 1656 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.47 (s, 4H, 2NCH₂), 7.20-8.20 (m, 22H, ArH's+2NH₂), 8.37 (s, 2H, D₂O-exchangeable 2NH), 10.06 (s, 2H, D₂O-exchangeable 2NH); ¹³C NMR [DMSO-*d*₆] δ 38.69, 93.57, 121.03, 121.22, 122.74, 124.10, 124.76, 126.64, 126.80, 129.46, 135.52, 152.87, 160.05, 163.95, 164.39. Anal. Calcd for C₄₀H₃₀O₄N₈S₄ (814.98): C, 58.95; H, 3.71; N, 13.75; S, 15.74. Found: C, 58.97; H, 3.73; N, 13.72; S, 15.71%.

***N,N'*-(Ethane-1,2-diyl)bis[4-amino-5-(benzopyran-3-carbonyl)-2-(phenylamino)]thiophene-3-carboxamide (16b).**

Green crystals, yield: 0.50 g (60%); mp >300 °C; IR (KBr): 3420-3333 (NH₂+2NH), 1646 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.37 (s, 4H, 2NCH₂), 6.75-7.49 (m, 24H, ArH's + 2 NH₂), 10.32 (s, 2H, D₂O-exchangeable 2NH), 11.97 (s, 2H, D₂O-exchangeable 2NH). Anal. Calcd for C₄₄H₃₂O₈N₆S₂ (836.89): C, 63.15; H, 3.85; N, 10.04; S, 7.66. Found: C, 63.17; H, 3.87; N, 10.06; S, 7.64%.

***N,N'*-(Ethane-1,2-diyl)bis[4-amino-5-(benzoyl)-2-(phenylamino)]thiophene-3-carboxamide (16c).**

Yellow crystals, yield: 0.48 g (68%); mp 292-293 °C; IR (KBr): 3317-3395(NH₂ + 2NH), 1638 (C=O)

cm⁻¹; insoluble in common NMR solvents; Anal. Calcd for C₃₈H₃₂O₄N₆S₂ (700.83): C, 65.12; H, 4.60; N, 11.99; S, 9.15. Found: 65.15; H, 4.62; N, 11.96; S, 9.16%.

ANTIMICROBIAL ACTIVITY

Compounds **5b**, **5c**, **14b** and **16b** were tested for their antimicrobial activities using four fungal species, namely *Aspergillus fumigatus* **AF**, *Penicillium italicum* **PI**, *Syncephalastrum racemosum* **SR** and *Candida albicans* **CA**. Also, four bacteria species namely, *Staphylococcus aureus* **SA**, *Pseudomonas aeruginosa* **PA**, *Bacillus subtilis* **BS** and *Escherichia coli* **EC** were tested. The organisms were tested against the activity of solutions of concentration of 1 mg/mL, 2.5 mg/mL and 5 mg/mL of each compound and using an inhibition zone diameter in cm (IZD) as criterion for the antimicrobial activity. The fungicide Terbinafin and the bactericide Chloramphenicol were used as references to evaluate the potency of the tested compounds under the same conditions. The results are summarized in Table 1.

Table 1. Antimicrobial activity of compounds **5b**, **5c**, **14b** and **16b**

Micro-organism/IZD (cm)*

Sample	5b mg/ml			5c mg/ml			14b mg/ml			16b mg/ml			Standard mg/ml		
	5	2.5	1	5	2.5	1	5	2.5	1	5	2.5	1	5	2.5	1
(AF)	++	++	+	0	0	0	0	0	0	0	0	0	+++	+++	++
(PI)	++	++	0	0	0	0	0	0	0	0	0	0	+++	+++	++
(SR)	0	0	0	0	0	0	+	+	+	0	0	0	+++	+++	+++
(CA)	++	++	+	0	0	0	0	0	0	0	0	0	++	++	++
(SA)	0	0	0	+	0	0	+	+	+	0	0	0	++	++	++
(PA)	0	0	0	+	0	0	0	0	0	+	+	+	+++	+++	++
(BS)	++	++	+	0	0	0	++	++	+	0	0	0	+++	+++	++
(EC)	0	0	0	0	0	0	0	0	0	0	0	0	++	++	++

* IZD beyond control/ (sign): 1.1-1.5 cm/ (+++); 0.6-1.0 cm/ (++); 0.1-0.5 cm/ (+); 0 cm (0).

CONCLUSION

In this report, a facile route for the synthesis of bis(6-mercaptopyridine), bis(pyrazolo[3,4-*b*]pyridine), bis(thienopyridine), bis(1,3,4-thiadiazole) and bis-thiophene derivatives starting from the readily accessible *N,N'*-(ethane-1,2-diyl)bis(cyanoacetamide) is described. The title compounds were synthesized as new products of biological interest and their structures were successfully established by elemental and spectral analyses.

REFERENCES

1. K. Hirai, Y. Iwano, T. Nishi, A. Yoshida, K. Oda, and H. Koyama, US Pat. 5,541,317 [*Chem. Abstr.*, 1996, **125**, 167690m].
2. Y. Momose and H. Odaka, PCT Int. Appl. WO 97 36,882 [*Chem. Abstr.*, 1997, **117**, 331478n].
3. A. Yoshida, H. Kogen, I. Hayakawa, K. Oda, T. Kasai, K. Shimada, Y. Yoshida, S. Ishihara, F. Saito, Y. Ohata, T. Koga, E. Kitazawa, and T. Tokui, JP 09,202,775 [*Chem. Abstr.*, 1997, **127**, 234181c].
4. J. D. Hinks, A. K. Takel, and E. Hunt, Int. Appl. WO 97 25,309 [*Chem. Abstr.*, 1997, **127**, 161997m].
5. J. Wrobel, Z. Li, A. Dietrich, M. McCaleb, B. Mihan, J. Sredy, and D. Sullivan, *J. Med. Chem.*, 1998, **41**, 1084.
6. L. Muthusubramanian, R. B. Mitra, S. Rajkumar, and V. S. Rao, *J. Chem. Technol. Biotechnol.*, 1998, **72**, 164.
7. S. I. Klein, M. Czekaj, C. J. Gardner, K. R. Guertin, D. L. Cheney, A. P. Spada, A. S. Bolton, K. Brown, D. Colussi, C. L. Heran, S. R. Morgan, R. J. Leadley, T. C. Dunwiddie, M. H. Perrone, and V. Chu, *J. Med. Chem.*, 1998, **41**, 437.
8. Z. Shraideh and A. K. Sallal, *Biomed. Lett.*, 1997, **54**, 233.
9. J. Bompard, L. Giral, G. Malicome, and M. Puygrenier, *Eur. J. Med. Chem.*, 1987, **22**, 139.
10. M. E. Schnute, M. M. Cudahy, and A. Scott; PCT Int. Appl. WO, 00 53, 610 [*Chem. Abstr.*, 2000, **133**, 222607g].
11. I. Adachi and Y. Hiramatsu, JP Pat., 03, 52, 890 [*Chem. Abstr.*, 1991, **115**, 71573t].
12. T. Ooe, M. Sano, H. Kobayashi, and M. Kudome, JP Pat., 07 53, 562 [*Chem. Abstr.*, 1995, **123**, 256681k].
13. S. Furuya, N. Choh, K. Kato, and S. Hinuma, PCT Int. Appl. WO 95 28, 405 [*Chem. Abstr.*, 1996, **124**, 202226t].
14. N. Cho, M. Harada, T. Imaeda, H. Matsumoto, Y. Hayase, S. Sasaki, S. Furuya, N. Suzuki, S. Okubo, K. Ogi, S. Endo, H. Ondo, and M. Fujino, *J. Med. Chem.*, 1998, **41**, 4190.
15. S. Miki, K. Fukuoka, M. Akita, J. Kawakami, S. Furuya, and Y. Ishimaru, PCT Int. Appl. WO 9909, 033 [*Chem. Abstr.*, 1999, **130**, 196644h].
16. N. Suzuki, H. Matsumoto, and S. Furuya, Eur. Pat. App. EP 781, 774 [*Chem. Abstr.*, 1997, **127**, 135807e].
17. S. Furuya, N. Choh, N. Suzuki, and T. Imada, PCT Int. Appl. WO 000,00,493 [*Chem. Abstr.*, 2000, **132**, 64179s].
18. S. Furuya, H. Matsumoto, Y. Hayase, N. Suzuki, and T. Imada; PCT Int. Appl. WO 97 41, 126

- [*Chem. Abstr.*, 1998, **128**, 13211f].
19. H. Vieweg, S. Leistner, J. Prantz, N. Bohm, and G. Wagner, *Pharmazie*, 1992, **47**, 841.
 20. A. G. Griffin and T. R. Britt, *J. Am. Chem. Soc.*, 1981, **103**, 4957.
 21. G. Galli, M. Laus, and A. S. Angeloni, *Makromol. Chem.*, 1986, **187**, 289.
 22. H. Ringsdorf, B. Schlarh, and J. Venzmer, *Angew. Chem., Int. Ed. Engl.*, 1988, **27**, 115.
 23. H. Finkelman, *Angew. Chem., Int. Ed.*, 1987, **26**, 816.
 24. C. Aguilera, M. Parra, and G. Fuentes, *Z. Naturforsch*, 1998, **53B**, 367.
 25. N. A. Kheder, Y. N. Mabkhot, and A. M. Farag, *Heterocycles*, 2008, **75**, 887.
 26. A. M. Farag, A. S. Mayhoub, S. E. Barakat, and A. H. Bayomi, *Bioorg. Med. Chem.*, 2008, **16**, 881.
 27. A. M. Farag, A. S. Mayhoub, S. E. Barakat, and A. H. Bayomi, *Bioorg. Med. Chem.*, 2008, **16**, 4569.
 28. A. M. Farag, Y. M. Elkholy, and K. A. Ali, *J. Heterocycl. Chem.*, 2008, **45**, 279.
 29. M. R. Shaaban, T. S. Saleh, and A. M. Farag, *Heterocycles*, 2007, **71**, 1765.
 30. M. R. Shaaban, T. S. Saleh, F. H. Osman, and A. M. Farag, *J. Heterocycl. Chem.*, 2007, **44**, 177.
 31. A. M. Farag, K. M. Dawood, and N. A. Khedr, *J. Chem. Res.*, 2007, 472.
 32. K. M. Dawood, A. M. Farag, and H. A. Abdelaziz, *Heteroatom Chem.*, 2007, **18**, 294.
 33. N. A. Hamdy, H. A. Abdel-Aziz, A. M. Farag, and I. M. I. Fakhr, *Monatsh. Chem.*, 2007, **138**, 1001.
 34. J. Guareschi, *Chem. Ber.*, 1892, **25**, 326.
 35. Z. Qian, H. Su, and C. T. Mathew, US Pat. 5,654,465, 1997 [*Chem. Abstr.*, 1997, **127**, 205355g].
 36. T. A. Hill, J. A. Sakoff, P. J. Robinson, and A. McCluskey, *Austr. J. Chem.*, 2005, **58**, 94.
 37. U. Schmidt and H. Kubitzek, *Chem. Ber.*, 1960, **93**, 1559.
 38. G. E. H. Elgemeie, M. M. M. Sallam, S. M. Sherif, and M. H. Elnagdi, *Heterocycles*, 1985, **23**, 3107.
 39. A. F. Hegarty, M. P. Cashman, and F. L. Scott, *Chem. Commun.*, 1971, **13**, 884.
 40. A. M. Farag and M. S. Algharib, *Org. Prep. Proced. Int.*, 1988, **20**, 521.
 41. S. N. Sawhney and J. Sing, *Indian J. Chem.*, 1970, **8**, 882.
 42. N. A. Ismail, *Egypt. J. Pharm. Sci.*, 1991, **30**, 685.
 43. P. Czerney and H. Hartmann, *J. Prakt. Chem.*, 1983, **325**, 551.
 44. R. M. Cowper and L. H. Davidson, *Org. Synth. Coll.*, 1943, **2**, 480.